

CORE BRIEF TO MANAGEMENT GROUP MEMBERS

MEETING HELD ON 21 JUNE 2018

This briefing sets out the key areas of discussion and decision. It aims to ensure the Management Group members have a common core brief to disseminate within their organisation.

1. Welcome and Introductions

The Chair welcomed members to the meeting.

2. Minutes of the Previous Meeting and Action Log

The minutes of the meeting held on 24 May 2018 were read and approved subject to agreement to refer a decision on changing the status quo for re-charge of immunology costs, now that data is available to facilitate a utilisation based re-charge, to the Finance Sub-group (MG18/030).

Members noted the action log and received an update on:

- MG049 BMT Investment in south Wales – where it was proposed to hold a workshop during Q3 to explore this complex issue. Noted that potentially expanding this to haematology was a very large and complex extension of the project that could be considered after the initial project was completed.
- MG057 NWIS Project on English Data – Issue of a closure report had been delayed due to staff sickness at NWIS.
- MG063 Implementation of 2018-21 ICP – The latest PET meeting was due to be held on 22 June; the notes would follow - Action closed.
- MG065 Integrated Performance Report – The Report would now be developed further to include spinal rehabilitation data. Members were reminded to provide feedback on the additions to the report.
- MG066 Provision of CHD services following NHSE consultation – Gap analysis to be brought to September meeting.

3. Report from the Managing Director

Members received the Managing Director's report. The report included updates on:

- Commissioning Arrangements for Pregnant Women with Acquired Heart Disease
- Neonatal Interim Work stream
- Paediatric Rheumatology
- Thrombectomy / Stroke Commissioning
- Home Parenteral Nutrition
- Proton Beam Therapy

- BAHA and Cochlear
- Critical Care

An oral update was given on the status of adult thoracic surgery consultation for south Wales.

4. Delivery Plan for the Five Year Neuroscience Strategy

Members received a paper that demonstrated how the five year specialised neurosciences strategy could be delivered and outlined the support required from health boards. Members were supportive of the paper and made suggestions as to how the paper could be supplemented and presented to Joint Committee.

Members:

- Supported the delivery plan for the five year strategy for specialised neurosciences, subject to their suggested revisions.

5. Funding Release for Second Spinal Rehabilitation Consultant

Members received a paper that requested support for the release of funding for an additional spinal rehabilitation consultant and administrative support for the Welsh Spinal Cord Injury Rehabilitation service to ensure sustainability and deliverability of the service, improve patient outcomes and make progress towards achieving BRSM standards.

Members:

- Supported the release of funding for the appointment of an additional spinal rehabilitation consultant and administrative support.

6. Cystic Fibrosis: Investment Case

Members received a paper that set out the investment requirements for the All Wales Adult Cystic Fibrosis Centre to address the immediate clinical risk and service sustainability issue, and support the ongoing development of the service.

Members:

- Noted the information presented in the report and the impact of non-investment; and
- Supported the investment for approval by the Joint Committee, recognising the need to do additional work to recognise the impact in the 2019-22 ICP.

7. Use of Crizotinib in the treatment of ROS1-positive advanced non small-cell lung cancer

Members received a paper that explained that NICE had issued the Final Appraisal Document guidance (FAD) for the use of Crizotinib in the treatment of ROS1-positive advanced non-small-cell lung cancer, which meant that NHS Wales would need to provide funding and resources for its use.

Members:

- Noted the information presented within the paper, including the requirement for the manufacturer to offer NHS Wales the same or similar package as NHS England including price, as part of the managed access agreement; and
- Approved the funding request for 2018/19 and 2019/20 and beyond.

8. PET: New indications

Members received a paper that (1) outlined the ICP scheme to fund additional PET indications (ICP17: 132) and confirm this is within the funded ICP 2018/19, (2) confirmed that the PET policy has been updated to include the new indications and published on the WHSSC website, and (3) outlined the financial and contract arrangements to support implementation of the additional indications for PET (ICP17:132).

Members:

- Noted the scheme ICP17:132 PET new indications is included within the funded plan;
- Noted the revised PET policy has been approved by WHSSC Policies Group and published on the WHSSC website in May 2018; and
- Noted the financial provision within the ICP for the additional indications and that work is in progress to incorporate the revised baseline within provider contracts.

9. Commissioning Policies: Approval Process

Members received a paper that provided an update on the work of the Policy and Service Specification Group and noted the contents of the report. Members asked that in future all draft policies should be issued for consultation as 'Policy proposals'. Members agreed that all policies must be presented to Management Group after completion of the consultation process for endorsement. These will then go to Joint Committee for formal approval where there are financial or service implications otherwise they will go for information only.

10. Integrated Performance Report

Members received a paper that provided members with a summary of the performance of services commissioned by WHSSC for April 2018 and details the action being undertaken to address areas of non-compliance.

Members:

- Noted the April 2018 performance and the action being undertaken to address areas of non-compliance.

11. Finance Report

Members received a report that set out the estimated financial position for WHSSC for the second month of 2018-19. No corrective action was required at this point. It was noted that the main continuing issue was HRG4+.

Members:

- Noted the current financial position and forecast year-end position.

12. Annual Report from Chair of Management Group

Members received a draft of the Annual report from the Chair of Management Group to the Joint Committee and were invited to provide details of any factual inaccuracies to the Committee Secretariat.

Members:

- Noted the content of the report; and
- Supported its submission to Joint Committee, subject to any appropriate revisions.

13. Annual Self-assessment

Members conducted a self-assessment of the performance of Management Group for the year ended 31 March 2018.

14. Any other business

There were no other items of business raised.